Last reviewed · How we verify
celecoxib reference formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
celecoxib reference formulation (celecoxib reference formulation) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| celecoxib reference formulation TARGET | celecoxib reference formulation | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- celecoxib reference formulation CI watch — RSS
- celecoxib reference formulation CI watch — Atom
- celecoxib reference formulation CI watch — JSON
- celecoxib reference formulation alone — RSS
Cite this brief
Drug Landscape (2026). celecoxib reference formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-reference-formulation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab